Point prevalence survey of antimicrobial utilization in oncology patients

  • Arwa Hammuda Qatar University, College of Pharmacy, Doha, Qatar
  • Sara Hayder Qatar University, College of Pharmacy, Doha, Qatar
  • Shereen Elazzazy Hamad Medical Corporation, National Center for Cancer Care and Research, Doha, Qatar
  • Emily Black Qatar University, College of Pharmacy, Doha, Qatar
Keywords: Antimicrobial therapy, antibiotic prescription, hospital

Abstract

Introduction: Point prevalence surveys have been used internationally to characterize the use of antimicrobial agents. The primary objective of this study was to determine prevalence of antimicrobial use in the oncology population in Qatar.

Methodology: Data was collected from the National Center for Cancer Care and Research hospital over 3 separate days during a two week period. Adults admitted on the day of audit were included.

Results: Prevalence of antimicrobial use during the audit was 43% (25/58). The most commonly prescribed class of antimicrobial agents was penicillin/Beta-lactamase inhibitor combinations 39.4% (13/33).

Conclusions: Findings demonstrate frequent antimicrobial consumption of broad spectrum antimicrobial agents which highlights the importance of expanding antimicrobial stewardship programs in this population.

Author Biographies

Arwa Hammuda, Qatar University, College of Pharmacy, Doha, Qatar
Qatar University
B.Sc(Pharm), M.Sc student
Sara Hayder, Qatar University, College of Pharmacy, Doha, Qatar

Qatar University

B.Sc (Pharm), PharmD student

Shereen Elazzazy, Hamad Medical Corporation, National Center for Cancer Care and Research, Doha, Qatar

Clinical Pharmacist, Hamad Medical Corporation, National Center for Cancer Care and Research

B.Sc(Pharm), PharmD

Emily Black, Qatar University, College of Pharmacy, Doha, Qatar

Assistant Professor at the College of Pharmacy, Qatar University

B.Sc (Pharm), PharmD, ACPR

Published
2013-12-15
How to Cite
1.
Hammuda A, Hayder S, Elazzazy S, Black E (2013) Point prevalence survey of antimicrobial utilization in oncology patients. J Infect Dev Ctries 7:990-993. doi: 10.3855/jidc.3126
Section
Brief Original Articles